200 results about "Parainfluenza virus" patented technology

The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and / or to rescue negative strand RNA recombinant viruses that express, package, and / or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.

The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and / or to rescue negative strand RNA recombinant viruses that express, package, and / or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.

The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and / or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

The invention discloses a respiratory pathogen multi-detection reagent kit. The respiratory pathogen multi-detection reagent kit has the advantages that the respiratory pathogen multi-detection reagent kit is based on multi-PCR (polymerase chain reaction) technologies, detection results can be determined by the aid of fluorescence resonance energy transfer via the melting temperature ranges, the respiratory pathogen multi-detection reagent kit can be used for qualitatively simultaneously detecting 16 types of respiratory pathogens, the 16 types of respiratory pathogens include 12 types of RNA(ribonucleic acid) viruses (influenza A viruses, influenza B viruses, H1N1 influenza A viruses, type A and type B respiratory syncytial viruses, type -1 / -2 / -3 parainfluenza viruses, type OC43 coronaviruses, type 229E coronaviruses, rhinoviruses and human metapneumovirus), 2 types of DNA (deoxyribonucleic acid) viruses (adenoviruses and bocavirus) and 2 types of bacteria (mycoplasma pneumoniae andbordetella pertussis), the respiratory pathogen multi-detection reagent kit is high in detection sensitivity, and the sensitivity even can reach 1 copy / reaction; the multi-detection reagent kit is good in specificity, and negative results of pathogens which have identical sampling sites and similar pathogenic mechanisms and are not in the detection range of the respiratory pathogen multi-detectionreagent kit can be obtained; the respiratory pathogen multi-detection reagent kit is short in operation time and easy to operate and can be used for quickly detecting the 16 types of respiratory pathogens in a single tube of a reaction system, the results are clear and are easy to interpret, and the like.

Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I:wherein the 1′ position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.

Recombinant human parainfluenza virus type 1 (HPIV1) compostions, formulations and methods are provided. The recombinant HPIV1 viruses and HPIV1 chimeric and chimeric vector viruses provided according to the invention are infectious and attenuated in permissive mammalian subjects, including humans, and are useful in immunogenic composition s for eliciting an immune responses against one or more PIVs, against one or more non-PIV pathogens, or against a PIV and a non-PIV pathogen. Also provided are isolated polynucleotide molecules and vectors incorporating a recombinant HPIV1 genome or antigenome.

The invention relates to a nano silver-selenium negative ion strongly-antibacterial aerosol for preventing and curing rhinitis and influenza, which can effectively achieve the purpose of killing bacteria and viruses. The rhinitis and the influenza are upper respiratory tract infection caused by multiple viruses, i.e. rhinoviruses, parainfluenza viruses, respiratory syncytial viruses, adenoviruses, and the like. No bacterium and virus can not be killed by silver within 6 minutes in a laboratory; the silver is a highly-effective broad-spectrum antimicrobial; selenium can eliminate internal free radicals, is anticancer and antiaging and can enhance immunity; tourmalines can generate air negative ions; and the aerosol prepared from nano micropowder obtained by mixing nano traditional Chinese medicine which has unique effect on the rhinitis and the influenza and propolis powder which has special effect on the influenza can effectively prevent and cure the rhinitis and the influenza.

The invention discloses a nucleic acid combined testing kit of respiratory tract infection pathogens. The invention develops a set of primer-probe combinations which can detect multiple types of respiratory tract infection pathogens such as novel coronavirus, influenza virus a, influenza virus b, respiratory syncytial virus, human parainfluenza virus, adenovirus, mycoplasma pneumonia and chlamydiapneumonia through combination of a multiple fluorescence quantitative PCR technology and a flow-through hybridization and gene chip technology, wherein nucleotide sequences thereof are shown by SEQ ID NO:1-36 respectively. The nucleic acid combined testing kit of the respiratory tract infection pathogens is established. The kid can realize synchronous combined testing of the 8 respiratory tract infection pathogens, is high in detection accuracy, specificity and sensitivity, good in repeatability, low in false negativity and false positivity, short in detection time and low in cost, can realize comprehensive detection of a patient, can locate a disease source accurately, can realize treatment in time or make corresponding quarantine measures and is of important significance to effective control of respiratory tract infection and subsequent prevention of outbreak of relevant contagion and infection.

The invention relates to a primer composite for detecting respiratory pathogens. The primer composite comprises at least one group of a mycoplasma pneumoniae group, a chlamydia pneumoniae primer group, an influenza A / B virus primer group, a parainfluenza virus primer group, an adenovirus primer group and a respiratory syncytial virus primer group. The invention further relates to a kit comprising the primer composite. The kit further comprises a micro-fluidic chip wrapping primers, and a macroscopic indicator. The invention further relates to a detection method adopting the primer composite. The detection method comprises the steps of primer composite coating, to-be-detected sample nucleic acid extraction, LAMP reaction and visual result interpretation. The kit and the method are applied to the micro-fluidic chip for visual judgment, instant detection of the seven respiratory pathogens is rapidly and accurately realized, and a result is judged by a naked eye by color change, so that the kit and the method are simpler, more convenient and quicker in practical applications, are easy to operate, and are suitable for site operation.

The present invention relates to methods for broad spectrum prevention and treatment of viral respiratory infection. In particular, the present invention relates to methods for preventing, treating or ameliorating symptoms associated with respiratory syncytial virus (RSV), parainfluenza virus (PIV), and / or human metapneumovirus (hMPV) infection, the methods comprising administering to a subject an effective amount of one or more anti-RSV-antigen antibodies or antigen-binding fragments thereof, one or more anti-hMPV-antigen antibodies or antigen-binding fragments thereof, and / or one or more anti-PIV-antigen antibodies or antigen-binding fragments thereof. In certain embodiments, a certain serum titer of the anti-RSV-antigen antibodies, anti-PIV-antigen antibodies, and / or anti-hMPV-antigen antibodies or antigen-binding fragments thereof is achieved in said subject. In certain specific embodiments, the subject is human and, preferably, the anti-RSV-antigen antibody, anti-PIV-antigen antibody, and / or anti-hMPV-antigen antibodies are human or humanized. The present invention relates further to compositions comprising the anti-RSV-antigen is antibodies, anti-PIV-antigen antibodies, and / or anti-hMPV-antigen antibodies or antigen-binding fragments thereof. The present invention also relates to detectable or diagnostic compositions comprising the one or more anti-RSV-antigen antibodies, anti-PIV-antigen antibodies, and / or anti-hMPV-antigen antibodies or antigen-binding fragments thereof and methods for detecting or diagnosing RSV, PIV and / or hMPV infection utilizing the compositions.

Multimeric hybrid genes encoding the corresponding chimeric protein comprise a gene sequence coding for an antigenic region of a protein from a first pathogen linked to a gene sequence coding for an antigenic region of a protein from a second pathogen. The pathogens particularly are parainfluenza virus (PIV) and respiratory syncytial virus (RSV). A single recombinant immunogen is capable of protecting infants and similar susceptible individuals against diseases caused by both PIV and RSV.

The present invention relates to C34 peptide derivatives that are inhibitors of viral infection and / or exhibit antifusogenic properties. In particular, this invention relates to C34 derivatives having inhibiting activity against human immunodeficiency virus (HIV), respiratory syncytial virus (RSV), human parainfluenza virus (HPV), measles virus (MeV), and simian immunodeficiency virus (SIV) with long duration of action for the treatment of the respective viral infections.

The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and / or to rescue negative strand RNA recombinant viruses that express, package, and / or present the heterologous gene product. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.

The present invention relates to recombinant bovine parainfluenza virus (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and / or to rescue negative strand RNA recombinant viruses that express, package, and / or present the heterologous gene product. In particular, the heterologous gene products include gene product of another species of PIV or from another negative strand RNA virus, including but not limited to, influenza virus, respiratory syncytial virus, human metapneumovirus and avian pneumovirus. The chimeric viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.